StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HANN.BK$0.92+0.00%
Fair $0.92+0.0%

HANN.BK

Mukdahan International Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$0.92

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.92Fund rank 34/100 · Data gapFallback financials|
SA 50/C
F-Score: 5/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $38.5M · quality 68.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 55/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

50/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

12/100

SEC 0%

Latest source: unknownPeriods: 3Warnings: 1unknown: 3
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years
Thesis & Journal · HANN.BKLocal privado en este navegador · Mukdahan International Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$515M

P/E

92.0x

↑

EV/EBITDA

6.3x

↓

ROE

7.3%

↑

Gross Margin

27.6%

↓

Debt/Equity

0.21

↓
52-Week Range$1
$1$3

TradingView lightweight chart

HANN.BK price, volumen y niveles de valoración

Último $0.920Periodo -56.6%
Fair value: $0.920

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2025 · 2 años de histórico normalizado

Revenue CAGR

-6.3%

FCF CAGR

-31.0%

FCF margin

8.3%

FCF / Net income

1.75x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $463.1M · net income $22.0M · FCF $38.5M

2023-FY → 2025-FY

Gross margin

27.6%-2.2% pts

Operating margin

3.0%-5.7% pts

Net margin

4.7%-0.5% pts

FCF margin

8.3%-7.0% pts
MetricTTM
2025
2024
2023
Income Statement
Revenue$463.1M$463.1M$492.5M$527.1M
Net Income$22.0M$22.0M$21.2M$27.8M
EBITDA$58.7M$58.7M$70.7M$90.7M
EPS0.050.050.040.05
Gross Margin27.6%27.6%30.5%29.8%
Operating Margin3.0%3.0%6.1%8.7%
Net Margin4.7%4.7%4.3%5.3%
Balance Sheet
Debt/Equity0.210.210.450.60
Current Ratio2.402.40——
Cash Flow
Free Cash Flow$38.5M$38.5M$7.8M$80.7M
Returns
ROE7.3%7.3%11.2%15.7%
Valuation
P/E92.0092.00——
EV/EBITDA6.336.33——
P/B1.421.42——
Growth & Yield
Revenue Growth-6.0%-6.0%-6.6%—
EPS Growth24.3%24.3%-23.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

20.2%

exigente

EPS terminal req.

$0.08

Spread vs growth

4.0%

5Y implied EPS CAGR

16.0%

exigente

EPS terminal req.

$0.10

Spread vs growth

8.2%

10Y implied EPS CAGR

13.0%

razonable

EPS terminal req.

$0.16

Spread vs growth

11.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -56.6%

Total return

-56.6%

Start / end P/E

56.0x → 19.6x

EPS bridge

0.04 → 0.05

Residual

-15.8%

EPS growth+24.3%
Multiple rerating-65.1%
Dividend+0.0%
Residual / FX / buybacks / cross-term-15.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.